AtCor Medical

AtCor Medical today announced that it has signed agreements to supply SphygmoCor® systems and clinical trial support services for upcoming pharmaceutical clinical trials. The minimum total value of these contracts is USD$1.15 million, a significant portion of which will be recognised as revenue in the current financial year. Over 70 percent of these transactions are repeat business following successful use of SphygmoCor® in earlier trials by the same client company. The new trials will take place at sites in the US and Europe.

Please click here to view the ASX/media release

Study Findings: 70% with ‘High Normal’ Blood Pressure at Risk

20 May 2008

A new study of more than 10,000 patients has found more than 70 per cent of patients identified as having ‘high-normal’ blood pressure through traditional cuff blood pressure measurement may be at risk because they have elevated central blood pressure associated with increased incidence of heart attack, stroke and kidney disease.

Please click here to view the ASX/media release

AtCor Medical Receives Russian Marketing Approval

7 May 2008

AtCor Medical announced today that it has received formal certification from the Russian Ministry of Health, allowing AtCor to market its SphygmoCor® non-invasive central blood pressure systems throughout Russia - a Potential Market of 400 systems over the next 3 years.

Please click here to view the ASX/media release

New Study Shows Central Blood Pressure Is Superior

23 April 2008

A new study has found that elevated Central Blood Pressure is superior to arm blood pressure, high cholesterol, and smoking as a predictor of heart attacks and strokes.

Please click here to view the ASX/media release

AtCor Medical Announces Third Quarter Report - Appendix 4C

15 April 2008

AtCor Medical today released its quarterly cash flow report for the period ending 31 March 2008.

Please click here to view the ASX/media release

Investor Presentation

10 April 2008

AtCor Medical today released their Investor Presentation for 2008.

Please click here to view the ASX/media release

AtCor Medical Released Half Year Results

22 February 2008

AtCor Medical Holdings Limited today released its H1 FY2008 results showing record sales of $3.1 million for the period.

Please click here to view the ASX/media release

AtCor Medical announces Record Half Year Sales - On track for 50% sales growth in FY

24 January 2008

AtCor Medical Holdings Limited today announced unaudited H1 FY2008 sales of $3.1 million, a 27 per cent increase in constant currency over H1 FY2007 and a record for the company.

Please click here to view the ASX/media release

AtCor Medical announces second quarter report - Appendix 4C

24 January 2008

AtCor Medical today released its quarterly cash flow report for the period ending 31 December 2007. The company has $4,571,000 in cash and equivalents.

Please click here to view the ASX/media release

AtCor Medical Investor Newsletter

19 December 2007

Please click here to view the ASX/media release

Rodman & Renshaw 9th annual healthcare conference presentation

7 November 2007

Please click here to view the ASX/media release

AtCor releases Commitments Test Entity – First Quarter Report

30 October 2007

Please click here to view the ASX/media release

Appendix 3B

26 October 2007

Please click here to view the ASX/media release

AtCor invited to present at Rodman & Renshaw 9th annual healthcare conference

22 October 2007

AtCor Medical today announced that it has been invited to present at Rodman & Renshaw 9th annual healthcare conference.

Please click here to view the ASX/media release

Change of Directors' Interest Notices

15 October 2007

AtCor Medical released change of Directors' Interest Notices

Please click here to view the ASX/media release

Notice of General Meeting / Proxy

11 October 2007

AtCor Medical today released Notice of General Meeting/Proxy.

Please click here to view the ASX/media release

Placement of Colonial's AtCor shares oversubscribed

9 October 2007

AtCor Medical announced placement of Colonial's AtCor shares has been oversubscribed.

Please click here to view the ASX/media release

AtCor Medical Annual Report 2007

28 September 2007

AtCor Medical today released its 2007 Annual Report.

Please click here to view the ASX/media release

ASX Preliminary Year End Information 2007

23 August 2007

AtCor has made significant progress in the last year, including:

1. The major increase in both contracted and recognised revenue.
2. The healthy geographic spread of this revenue with all regions of the world performing well.
3. The emergence of the significant opportunity that the pharma sector presents.
4. The continued endorsement of our technology through, for example:
a. the guidelines issued jointly by the European Society of Hypertension and the European Society of Cardiology which state that important drug effects can only be seen with central pressure measurement and not using traditional brachial (cuff) blood pressure monitoring; and,
b. the US National Institute of Health (NIH) funded Strong Heart study that found that central pulse pressure was a superior predictor of all cardiovascular events than brachial pulse pressure.
5. The award of a $2.0 million commercial ready grant by AusIndustry to fund our next generation technology.

Please click here to view the ASX/media release

AtCor Medical announces FY2007 contracted revenue increases 86% to $6.3 m

26 July 2007

AtCor Medical today announced record sales for FY2007. New business closed in FY2007 of $6.3 million is an 86 per cent increase over FY2006 ($3.4 million) and comprises $4.8 million (unaudited) in recognised revenue for FY2007 and a further $1.5 million which will be recognised in future periods.

Please click here to view the ASX/media release

AtCor Medical announces fourth quarter report - Appendix 4C

26 July 2007

AtCor Medical today released its quarterly cash flow report for the period ending 30 June 2007. The company has $6,999,000 in cash and equivalents.

Please click here to view the ASX/media release

AtCor announces pharmaceutical trial contract with new US client

18 July 2007

AtCor Medical today announced that it has signed a contract to supply SphygmoCor systems and clinical trial support services to a leading international pharmaceutical company, headquartered in the United States.

Please click here to view the ASX/media release

AtCor Signs US$1.3 Million New Pharmaceutical Contracts

3 July 2007

AtCor Medical has signed agreements with two leading international pharmaceutical companies to supply SphygmoCor systems and clinical trial support services for new and ongoing drug trials in Europe and the United States. The total value of the contracts is approximately US $1.3 million.

Please click here to view the ASX/media release

AtCor Appoints Distributors for China and India

7 June 2007

AtCor Medical has strengthened its Asian sales network with the appointment of distributors in the People's Republic of China and India. The company has also re-signed distributors in Malaysia and Singapore.

Please click here to view the ASX/media release

US National Institute of Health funded trial concludes: Central pulse pressures a better predictor of cardiovascular risk and disease

29 May 2007

AtCor Medical today announced that the results from the US National Institute of Health’s funded Strong Heart Study have concluded central blood pressures are a better predictor of future cardiovascular outcomes than traditional brachial (cuff) blood pressure.

Please click here to view the ASX/media release

AtCor Awarded $2 Million Commercial Ready Grant

23 May 2007

AtCor Medical today announced that it has been awarded a grant of approximately $2 million through the Australian Government's AusIndustry Commercial Ready program.

Please click here to view the ASX/media release

AtCor Extends Distribution to Eastern Europe

30 April 2007

AtCor Medical has expanded its European distribution network to sixteen countries with the appointment of distributors in Eastern Europe.

Please click here to view the ASX/media release

AtCor Medical and Encorium Group, Inc. Announce Alliance for Clinical Research Trials

21 March 2007

AtCor Medical and Encorium Group Inc., an international, full service contract research organization (CRO) that provides comprehensive clinical solutions for pharmaceutical, biotechnology and medical device companies, today announced a joint marketing agreement for products and services that is anticipated to strengthen the fundamental value offerings of both companies.

Please click here to view the ASX/media release

Investor Update March 2007

16 March 2007

AtCor Medical today released their Investor Presentation for March 2007.

Please click here to view the ASX/media release

US gridiron players' central blood pressures tested during Super Bowl Week

13 February 2007

AtCor Medical advises that the SphygmoCor system was used to assess retired NFL players' cardiovascular risk during Super Bowl Week in the United States. These monitoring sessions, which generated print, broadcast and internet media coverage, helped to raise awareness of the importance of measuring central blood pressure using SphygmoCor.

An interview with Dr Roberts, founder and head of The Living Heart Foundation which sponsored the testing at Miami, can be seen via the link below. Dr Roberts is a retired cardiac surgeon and former quarterback for the Cleveland Browns and Miami Dolphins.

Please click here to view the interview

Please click here to view the ASX/media release

52% increase in first half sales

24 January 2007

AtCor Medical announces a 52 per cent increase in unaudited H1 FY2007 sales over H1 FY2006. Sales revenue for the six months ended 31 December 2006 was $2.6 million, compared to $1.7 million for the previous corresponding period.

In the United States, sales increased by 90 per cent in H1 FY2007 compared to H1 FY2006, and sales opportunities also increased significantly. In Europe, new distribution agreements and expanded contracts with existing distributors helped sales grow by 67 per cent.

Please click here to view the ASX/media release

AtCor Medical optimistic about future demand

9 November 2006

At the annual general meeting of AtCor Medical chairman Donal O'Dwyer said that AtCor had made a great deal of progress to position itself for greater revenues from its SphygmoCor® system, which measures central blood pressure non-invasively.

Providing an update on AtCor's progress in the United States, AtCor chief executive officer Duncan Ross said the company had a strong market opportunity in the pharmaceutical sector, and was on track to more than double US revenues. AtCor has had a robust start to the financial year, gaining the single largest order in the company's history - a US$1.5 million sale to a mid-sized US pharmaceutical company. In addition, AtCor has more than doubled its sales opportunity pipeline from under US$1.0 million to over US$2.5 million.

Please click here to view the ASX/media release

AtCor Medical first quarter report - Appendix 4C

31 October 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 30 September 2006. The company has $9,929,000 in cash and equivalents.

Please click here to view the ASX/media release

AtCor Medical Signs European Distributors. Appoints Asia-Pacific Sales and Marketing Manager.

11 October 2006

AtCor Medical today announced new distribution agreements to sell SphygmoCor in Spain, Switzerland, Benelux, Portugal and Scandinavia, and contract renewal with its distributors in United Kingdom/Ireland, Austria and Greece. The new agreements strengthen significantly AtCor's European marketing and distribution.

In addition, AtCor has focused its sales efforts in Asia-Pacific with the appointment of Tony Doherty to the newly created position of international sales and marketing manager. Mr. Doherty will be based in Sydney, and responsible for building sales outside the United States and Europe, particularly in Asia-Pacific. He has strong cardiovascular experience in Asian markets, and joins AtCor from Draeger and Siemens Medical, both world leading manufacturers of medical equipment.

Please click here to view the ASX/media release

AtCor Medical Annual General Meeting

5 October 2006

AtCor Medical today announced that the 2006 Annual General Meeting (AGM) of the Company will be held at Level 16, 60 Castlereagh St, Sydney, NSW 2000 on Thursday, 9 November, 2006 commencing at 11:00 am.

Please click here to view the ASX/media release

Investor Presentation

26 September 2006

AtCor Medical today released their Investor Presentation for 2006.

Please click here to view the ASX/media release

AtCor Medical appoints new CEO

25 September 2006

AtCor Medical today announced that Mr. Duncan Ross will become chief executive officer of the company at the annual general meeting on 9 November 2006.

Mr Ross is currently president and CEO of AtCor's North American business. He has over 23 years experience in the clinical diagnostics and life sciences device industry and for four years was president of Apogent Technologies' and Fisher Scientific Products' laboratory equipment group, the number two supplier in the global $2.8 billion laboratory equipment market.

Please click here to view the ASX/media release

ASX Preliminary year end information

6 September 2006

This has been a year of significant progress for AtCor Medical. We are able to report that a great deal has been accomplished and we have achieved many of the key milestones towards successful commercialisation of our SphygmoCor system.

Please click here to view the ASX/media release

US$1.5 million sale to US pharmaceutical company

31 August 2006

AtCor Medical has completed an agreement with a United States-based pharmaceutical company to supply SphygmoCor systems and clinical trial support services for a US multi-centre clinical trial. The total value of the contract is US$1.48 million.

Please click here to view the ASX/media release

AtCor Medical fourth quarter report - Appendix 4C

28 July 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 30 June 2006. The company remains in a strong financial position with $11,811,000 in cash.

Please click here to view the ASX/media release

Shareholder's Newsletter

18 July 2006

AtCor Medical today releases its first Shareholder's Newsletter outlining the many exciting achievements for AtCor Medical since listing on the ASX last November.

Please click here to view the ASX/media release

Version 8 Software

10 July 2006

AtCor Medical is pleased to announce the release of SphygmoCor® Cardiovascular Management Suite Version 8, a new system software package that offers enriched clinical data and reporting capabilities, and provides a platform for development of future products, such as Heart Rate Variability.

Cardiovascular Management Suite clinical screens and reports provide central blood pressure parameters proven clinically significant in the recent CAFE and Strong Heart Studies (click here to view the CAFE and Strong Heart flyer), with these data reported in an expanded format from V7.1 against age- and gender-specific reference norms (click here to view the McEniery abstract).

For pulse wave velocity assessment, the Cardiovascular Management Suite reports PWV values – for the first time – against reference norms. This is especially important given the recent publication by Kullo, et al documenting the association between aortic pulse wave velocity and the presence and quantity of coronary artery calcium (click here to view the Kullo abstract).

Please refer to the detailed overview presentation that summarizes the new software package and provides a brief overview of the changes from Version 7.1. Click here to view the presentation.

Version 7.1 will remain available for supply and be supported for existing customers. For further enquiries regarding Version 8 or earlier versions of the software, please contact your local AtCor Medical representative, or send us an enquiry from our webpage here.

Medical Services Advisory Committee

16 June 2006

AtCor Medical has been advised by the Australian Medical Services Advisory Committee (MSAC) that the initial application for public funding has been unsuccessful.

Ross Harricks, AtCor Medical chief executive officer, said that the company would work with the Department of Health and Ageing and MSAC to lodge a new application.

Mr Harricks also stated that the MSAC decision would not affect the company’s progress. AtCor Medical is currently focused on building sales in the key United States market, and more than 900 SphygmoCor systems have been sold to research centres, hospitals and pharmaceutical companies worldwide, predominantly in the US and Europe. These include Mayo Clinic, Johns Hopkins University and Harvard Medical Centre.

Please click here to view the ASX/media release

AtCor Medical appoints President to build North American business

4 May 2006

AtCor Medical has appointed Duncan R Ross as President and CEO of its North American business, AtCor Medical Inc. In this newly-created role, Mr Ross will build and develop AtCor Medical’s sales and marketing program, which is being rolled out in the United States.

Mr Ross brings to AtCor over 23 years of experience in positions of increasing responsibility in the clinical diagnostics and life sciences device industry. Mr Ross was for four years President of Apogent Technologies' and Fisher Scientific Products Laboratory Equipment Group, the number two supplier in the global $2.8 billion laboratory equipment market.

Please click here to view the ASX/media release

AtCor Medical third quarter report - Appendix 4C

28 April 2006

AtCor Medical today releases its quarterly cash flow report for the period ending 31 March 2006. The company remains in a strong financial position with $13,280,000 in cash.

Please click here to view the ASX/media release

Major pharmaceutical company purchases SphygmoCor systems

21 March 2006

AtCor Medical Holdings Limited (ASX:ACG) today announced that it has received a significant order from US-based Novartis Pharmaceuticals Corporation, which uses the SphygmoCor system in its cardiovascular drug trials. This order, valued at approximately $300,000, follows Novartis’ purchase of SphygmoCor systems in 2005.

Please click here to view the ASX/media release

Major medical study publications endorse importance of SphygmoCor

13 March 2006

AtCor Medical Holdings Limited today announced that the Conduit Artery Function Evaluation (CAFE) study principal results published this week, and related commentaries in leading medical journals The Lancet and Circulation, provide a powerful endorsement for SphygmoCor.

Please click here to view the ASX/media release

AtCor Medical first half revenue up 40 percent - Investor Presentation

2 March 2006

AtCor Medical Holdings Limited today confirmed sales of $1.73 million for the six months to 31 December 2005, up 40 percent compared to the previous corresponding period.

Please click here to view the ASX/media release

AtCor Medical half-year financial report

2 March 2006

AtCor Medical Holdings Limited today released the financial report and accounts for the six months to 31 December 2005.

Please click here to view the ASX/media release

AtCor Medical second quarter report - Appendix 4C

30 January 2006

AtCor Medical Holdings Limited today announced sales of $1.73 million for the six months to 31 December 2005, up 40 percent compared to the previous corresponding period.

The company sold 95 SphygmoCor units to medical research centres and pharmaceutical companies worldwide, including a strong increase in sales in the United States. Sales included a significant order from Novartis, a major pharmaceutical company, for use in an international multi-centre clinical trial.

Please click here to view the ASX/media release

SphygmoCor endorsed by two major international clinical trials

14 November 2005

Two major outcome trials both utilising the SphygmoCor System were presented at the American Heart Association meeting yesterday. The studies clearly demonstrate the importance of central blood pressure measurements in assessing cardiovascular risk and the effects of pharmacologic therapy on clinical outcomes. AtCor Medical has issued an ASX/media release regarding these studies.

Please click here to view the ASX/media release

AtCor Medical Lists on the ASX

9 November 2005

At 12pm today AtCor Medical listed on the Australian Stock Exchange under the ASX code “ACG”. The $15 million initial public offering was over-subscribed.

Please click here to view the Prospectus.

AtCor Medical Launches on medcompare.com

22 August 2005

AtCor Medical products are now included in the medcompare.com online buyer's guide for medical professionals. The medcompare.com website, contains product information and a comparison tool that allows physicians, surgeons, and procurement personnel to review medical products and specifications online. The site is designed to help medical professionals decide which products are appropriate for their practice, and provides easy-to-use tools for the user to request additional product information or price quotes. News and targeted eNewsletters are also part of Medcompare's online network of information.

AtCor Medical Closes Financial Year with 25% Revenue Growth

15 July 2005

AtCor has closed its financial year to 30 June 2005 with an increase in revenue of 25% over the previous year. “This growth has come primarily from North America where we have been expanding our direct organization”, said AtCor Medical CEO, Ross Harricks.

SphygmoCor Adopted By Leading US Cardiovascular Prevention Center

10 June 2005

AtCor Medical’s SphygmoCor Px Pulse Wave Analysis system has been adopted by Colorado Heart and Body Imaging of Denver, one of the most technologically advanced and versatile prevention programs in the United States. Colorado Heart and Body Imaging plans to make sophisticated pulse wave analysis an integral part of its preventive cardiology services and is working closely with the AtCor Medical team in both the clinical and research arenas.

“I believe that one should get a fuller picture of cardiovascular risk than can be achieved by just assessing anatomy through today’s advanced imaging modalities”, noted James Ehrlich, MD, Colorado Heart and Body Imaging’s founder and medical director, “With SphygmoCor, we add an ability to non-invasively understand haemodynamics and arterial physiology, especially in patients with hypertension, diabetes, and metabolic syndrome. Furthermore, tracking progress to lifestyle changes or medications is made easy with SphygmoCor, and to me that is a distinct advantage. The addition of this exciting modality from Australia extends our reputation of using ‘best of breed’ technologies from around the world for the early detection and assessment of cardiovascular disease”

SphygmoCor Version 7.1 Launched

2 May 2005

AtCor today launched its latest version of the SphygmoCor software suite. Key user benefits are:

gender-specific “normal” values for SphygmoCor’s key central parameters, based on an expanded database of 4,000 patients (clinical study in press)
improved quality assessment of user’s captured raw data waveforms
adaptations for US market requirements

NIH-funded University of Pennsylvania Study Selects SphygmoCor

4 April 2005

SphygmoCor systems have been selected for a national multi-centre study in the USA, funded by the NIH, to look at the development of cardiovascular risk in patients with chronic renal disease. The project, a sub study of the CRIC trial, will be led by Dr Raymond Townsend, at University of Pennsylvania.

New SphygmoCor Tonometer Enhancement Launched

14 March 2005

After research and field trials, AtCor today launched a new tonometer sleeve that can be retro-fitted to existing tonometers to make the capture of high quality peripheral artery blood pressure waveforms much easier and quicker. There has been a strong positive response to the new tonometer, particularly from new SphygmoCor users.

Australian Medical Advisory Group Established

14 February 2005

AtCor Medical has established an Australian-based Medical Advisory Group to advise the company’s Sydney head office on the medical issues relating to its international business development. The Group comprises Prof Albert Avolio, Prof Marc Budge, Prof. David Celermajer, Dr Chris Hayward, Prof. Stephen McMahon, and Prof Tom Marwick. The group held its inaugural meeting today.

Boehringer Ingelheim Chooses SphygmoCor for International Clinical Trial

7 February 2005

International pharmaceutical company, Boehringer Ingelheim (Ingelheim, Germany) has selected SphygmoCor systems for a new international stroke trial it is commencing in April in twelve sites around the world.

Lisa McIntyre Appointed to AtCor Medical Board

20 January 2005

Dr Lisa McIntyre has been appointed to the Board of AtCor Medical. Lisa is a Director with L.E.K. Consulting Pty Ltd where she leads the Asia Pacific Life Sciences practice. She has over twelve years consulting in the life sciences and biopharmaceutical industries and has worked with more than 70 clients across a wide range of projects. Dr. McIntyre recently relocated to Sydney after over 9 years in the United States. Lisa is a Director of the Garvan Institute of Medical Research, and a Director of Biotech Capital Ltd.

AtCor Medical Establishes US Scientific Advisory Committee

10 November 2004

AtCor Medical’s US Scientific Advisory Committee has been established, chaired by Dr. Myron Weisfeldt, the William Osler Professor of Medicine and Director of the Department of Medicine at Johns Hopkins University. The Committee, which held its first meeting in conjunction with the American Heart Association meeting in New Orleans, advises AtCor Medical on scientific and medical issues related to the Company’s expansion in the US market.

Donal O’Dwyer Appointed Chairman of AtCor Medical

12 August 2004

Mr Donal O’Dwyer was appointed as Chairman of AtCor Medical at today’s Board of Directors meeting. Mr Peter Jenkins steps down as Chairman after 4 years and will continue as a Director on the Board. Mr O’Dwyer relocated to Australia in January 2004 from the USA, having retired as worldwide President of Cordis Cardiology, the cardiology devices business of Johnson & Johnson. Prior to joining Cordis in Europe, he worked for 12 year in Europe with Baxter Healthcare, where he rose to be President of the Baxter’s European Cardiovascular group.

Genzyme Expands Utilisation of SphygmoCor Systems

4 June 2004

Genzyme-Europe has expanded the use of SphygmoCor systems to an additional 20 centres in their CORD renal clinical trial. The new centres are located in Denmark, Sweden, Finland, and Norway. This expansion brings the number of CORD study sites to 40 with the original sites in Belgium and the Netherlands.

AtCor Medical Lodges Application with the Medical Services Advisory Committee (MSAC) to Commence Process for Australian Reimbursement.

5 May 2004

AtCor Medical has lodged an application to MSAC, Australia’s medical technology assessment body, to review its SphygmoCor technology. The Company’s objective in this new application is to gain MSAC recommendation to the Department of Health for the allocation of a reimbursement item number in the federal medical benefits schedule for the clinical use of SphygmoCor. This review process is likely to be completed by the end of 2005.

AtCor Medical Appoints Two Senior Executives in its US Operations

12 April 2004

AtCor Medical today announced the establishment of the Company’s United States subsidiary, AtCor Medical, Inc. (USA), and the appointment of Douglas T. Kurschinski and Dr. Dean C. Winter to the leadership positions of Vice President – Market Development, and Vice President – Clinical and Scientific Affairs, respectively.

Mr. Kurschinski comes to AtCor Medical with over 13 years experience in the US cardiovascular device industry, most recently as Director of Global Clinical Applications at Stereotaxis, Inc. of St. Louis, MO. Prior to that, he served as Director of North American Sales at Cardiac Pathways Corporation in Sunnyvale, CA and held positions in clinical research and business development with St. Jude Medical and Cardiac Pacemakers, Inc, both of St. Paul, MN. He holds a Bachelor’s Degree in Biomedical Engineering from the University of Iowa and an MBA from the University of Chicago.

Dr. Winter joins AtCor Medical from nearly 20 years at Southwest Research Institute in San Antonio, TX, where he was the Director of the Bioengineering Department. While at Southwest, he led the development of a number of innovative clinical medical devices, including the first commercially available arterial tonometer and numerous enhancements to automatic blood pressure monitoring systems. Dr. Winter was formerly on the faculty of mechanical engineering at the University of Houston and the State University of New York at Stony Brook. He holds a doctorate degree in Mechanical Engineering from Colorado State University, a Master’s Degree in Aeronautics and Astronautics from Stanford University, and a Bachelor’s Degree in Aeronautical Engineering from Purdue University.

AtCor Medical Completes A$3.7m New Funding Round

19 March 2004

The current investors in AtCor Medical, led by Colonial First State Private Equity, have made an additional investment of A$3.7m in the company, primarily to accelerate the expansion of its US Operations.

AtCor Completes First FDA Quality System Inspection

12 September 2003

AtCor Medical received notice from the FDA that in their first Establishment Inspection of their West Ryde, Sydney development and production facilities, conducted in June, AtCor Medical met the requirements of FDA QS/GMP regulations.

New European Hypertension Guidelines Acknowledge SphygmoCor

16 June 2003

The new European Society for Hypertension / European Society for Cardiology guidelines for managing hypertension and cardiovascular risk were presented at the ESH annual meeting in Milan.

The guidelines acknowledge "the pulse wave velocity measurement and the augmentation index measurement device (SphygmoCor)", "particularly in view of the claim that aortic blood pressure (and therefore the pressure exerted on the heart and brain) may be different from that which is usually measured at the arm, may be predictive of outcomes, and may be differently affected by different antihypertensive drugs"